Coherus Biosciences | CHRS - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Akebia Therapeutics USD 47.28M 1.7M 2025-12
ALKERMES USD 338.34M 72.51M 2025-12
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amarin USD 23.17M 961K 2025-12
Amgen USD 6.89B 415M 2025-12
Baxter International USD 891M 314M 2026-03
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Fujifilm JPY 347.51B 14.74B 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
Merck USD 10.85B 2.57B 2025-12
Myriad Genetics USD 146.8M 3M 2025-12
Pacira USD 126.64M 15.61M 2026-03
Perrigo USD 362.2M 14.9M 2025-12
Pfizer USD 12.28B 8.74B 2025-12
PTC Therapeutics USD 148.38M 39.31M 2025-12
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03
Xencor USD 21M 22.61M 2025-09
Zoetis USD 1.64B 73M 2025-12